Summary
- Current Price
- As of today, RNAM price is $71.34, with unknown change on
- Current Price All-Time High
- RNAM price is currently -2.35% below its historical high of $73.06 set on
- Market Cap
- RNAM current market cap is $11B, up +209.93% over the past 365 days
- PE Ratio
- RNAM PE ratio is unknown
- Revenue
- RNAM current annual revenue is $18.76M, up +72.11% year-over-year
- Next Earnings
- The next earnings release for RNAM is on
Profile
| Metric | Value |
|---|---|
| Full Name | Avidity Biosciences Inc |
| Ticker | NASDAQ: RNAM |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | aviditybiosciences.com |
| Employees | 511 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $71.34 | |
| Price, 1D Change | - | |
| Market Cap | $11B | |
| - | ||
| PE Ratio | - | |
| Beta | 0.96 | |
| Revenue | $19M | |
| Revenue, 1Y Change | +72.11% | |
| EPS | -$4.97 | |
| EPS, 1Y Change | -72.11% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | RNA | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$4.97 | |
| EPS Estimate | N/A | -$5.05 |
| EPS Est. Change | N/A | -1.63% |
| Revenue | $18.76M | |
| Revenue Estimate | N/A | $14.24M |
| Revenue Est. Change | N/A | -24.09% |
| Current Price | $71.34 | |
| Price Target | - | $72.00 |
| Price Tgt. Change | - | +0.92% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$5.05 | N/A | - | |
| -$3.80 | N/A | - |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $14.24M | N/A | - | |
| $296.12M | N/A | - |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +141.18% | |
| Price, 3Y | +247.50% | |
| Market Cap, 1Y | +209.93% | |
| Market Cap, 3Y | +658.13% | |
| Revenue, 1Y | +72.11% | |
| Revenue, 3Y | +103.33% | |
| EPS, 1Y | -72.11% | |
| EPS, 3Y | -49.04% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $71.34 | |
| SMA 200 | $53.27 | |
| SMA 200 vs Price | -25.33% | |
| SMA 50 | $72.31 | |
| SMA 50 vs Price | +1.35% | |
| Beta | 0.96 | |
| ATR | $0.22 | |
| 14-Day RSI | 27.68 | |
| 10-Day Volatility | 9.86% | |
| 1-Year Volatility | 74.34% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $18.76M | |
| EPS | -$4.97 | |
| Gross Profit | $14.60M | |
| Gross Margin | 77.87% | |
| Operating Profit | -$745.94M | |
| Operating Margin | -3,977.30% | |
| Net Income | -$684.63M | |
| Net Margin | -3,650.39% | |
| EBITDA | -$741.79M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.03 | |
| 9.20 | ||
| 9.20 | ||
| - | ||
| 1 | ||
| 23.15 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| 587.62 | ||
| 6.53 | ||
| -12.64 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $1.69B | |
| $1.70B | ||
| $1.96B | ||
| $1.80B | ||
| $269.45M | ||
| $195.45M | ||
| Total Debt | $49.25M | |
| $3.94M | ||
| $12.40M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $703.39M | ||
| $760.55M | ||
| $4.15M | ||
| $0.00 | ||
| $4.15M | ||
| $0.00 | ||
| $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| -$650.44M | ||
| -$38.04M | ||
| $850.99M | ||
| Capex | $13.32M | |
| -$663.76M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Chardan Capital | → | |
| TD Cowen | → | |
| RBC Capital | → | |
| Chardan Capital | → | |
| Raymond James | → | |
| Needham | → | |
| Leerink Partners | → | |
| HC Wainwright & Co. | → | |
| Citigroup | → | |
| Bernstein | → |
Analyst sentiment
Institutional ownership
Screeners with RNAM
FAQ
What is the ticker symbol for Avidity Biosciences Inc?
The ticker symbol for Avidity Biosciences Inc is NASDAQ:RNAM
Does Avidity Biosciences Inc pay dividends?
No, Avidity Biosciences Inc does not pay dividends
What sector is Avidity Biosciences Inc in?
Avidity Biosciences Inc is in the Healthcare sector
What industry is Avidity Biosciences Inc in?
Avidity Biosciences Inc is in the Biotechnology industry
What country is Avidity Biosciences Inc based in?
Avidity Biosciences Inc is headquartered in United States
When did Avidity Biosciences Inc go public?
Avidity Biosciences Inc initial public offering (IPO) was on June 12, 2020
Is Avidity Biosciences Inc in the S&P 500?
No, Avidity Biosciences Inc is not included in the S&P 500 index
Is Avidity Biosciences Inc in the NASDAQ 100?
No, Avidity Biosciences Inc is not included in the NASDAQ 100 index
Is Avidity Biosciences Inc in the Dow Jones?
No, Avidity Biosciences Inc is not included in the Dow Jones index
When was Avidity Biosciences Inc last earnings report?
Avidity Biosciences Inc's most recent earnings report was on March 2, 2026
When does Avidity Biosciences Inc report earnings?
The next expected earnings date for Avidity Biosciences Inc is May 11, 2026
Data Sources & References
- RNAM Official Website www.aviditybiosciences.com
- RNAM Profile on Yahoo Finance finance.yahoo.com/quote/RNAM
- RNAM Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/rnam